Currently, severe LAD1 patients with less than 2% CD18 expression are successfully treated with bone marrow and other hematopoietic stem cell transplantation (HSCT) therapies (Jamal et al., 1998; Elhasid and Rowe, 2010; Stepensky et al., 2015). Here, ITGB2 is linked to leukocyte adhesion deficiency 1.